ClinicalTrialsFinder

RecruitingPhase 2Phase 3NCT02131753

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Sponsor

University of Giessen

Enrollment

210 participants

Start Date

May 1, 2004

Study Type

INTERVENTIONAL

Conditions

Hairy Cell Leukemia

Summary

The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This trial is optimizing the treatment of hairy cell leukemia (a rare, slow-growing blood cancer) by comparing different chemotherapy approaches to find the most effective and safest option for patients who have never been treated before. **You may be eligible if...** - You are 18 or older - You have been diagnosed with hairy cell leukemia, confirmed by a bone marrow biopsy - You have never received chemotherapy for this condition (though a prior splenectomy or interferon treatment is allowed) - Your cancer requires treatment - Your general health status is acceptable (WHO 0–2) - Your diagnosis is based on a tissue sample taken within the past 6 months **You may NOT be eligible if...** - You have a variant form of hairy cell leukemia (HCL-V) - You have previously received purine analogue chemotherapy or other cancer drugs - You have serious heart, lung, liver, or kidney disease - You have HIV, active hepatitis, or other active infections Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCladribine s.c. injection, HCL treatment

Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection

Locations(76)

Community based hemato-oncology medical office

Ansbach, Germany

Community based hemato-oncology medical office

Aschaffenburg, Germany

Rhön-Saale-Klinik gGmbH

Bad Neustadt an der Saale, Germany

Community based hemato-oncology medical office

Berlin, Germany

Charité - Universitätsmedizin Berlin

Berlin, Germany

Community based hemato-oncology medical office

Bremen, Germany

Community based hemato-oncology medical office

Celle, Germany

Community based hemato-oncology medical office

Cottbus, Germany

Community based hemato-oncology medical office

Darmstadt, Germany

Community based hemato-oncology medical office

Dresden, Germany

Community based hemato-oncology medical office

Duisburg, Germany

Klinik Duisburg-West

Duisburg, Germany

Universitätsklinik Düsseldorf

Düsseldorf, Germany

Community based hemato-oncology medical office

Ehingen, Germany

Community based hemato-oncology medical office

Erlangen, Germany

Community based hemato-oncology medical office

Frankfurt, Germany

Krankenhaus Nordwest

Frankfurt, Germany

Community based hemato-oncology medical office

Freiburg im Breisgau, Germany

Community based hemato-oncology medical office

Friedrichshafen, Germany

Community based hemato-oncology medical office

Fürth, Germany

Community based hemato-oncology medical office

Germering, Germany

Community based hemato-oncology medical office

Giessen, Germany

University Clinic | Medicinal Clinic IV

Giessen, Germany

St.-Marien-Hospital

Hagen, Germany

Community based hemato-oncology medical office

Halle, Germany

Evangelisches Krankenhaus

Hamm, Germany

Community based hemato-oncology medical office

Hanau, Germany

Community based hemato-oncology medical office

Heidelberg, Germany

Community based hemato-oncology medical office

Herne, Germany

Marienkrankenhaus

Herne, Germany

Community based hemato-oncology medical office

Homberg (Ohm), Germany

Community based hemato-oncology medical office

Kaiserslautern, Germany

Städtisches Klinikum

Karlsruhe, Germany

Community based hemato-oncology medical office

Kassel, Germany

Klinikum Kempten-Oberallgäu

Kempten, Germany

Community based hemato-oncology medical office

Koblenz, Germany

Community based hemato-oncology medical office

Krefeld, Germany

Community based hemato-oncology medical office

Kronach, Germany

Community based hemato-oncology medical office

Landau, Germany

Community based hemato-oncology medical office

Landshut, Germany

Community based hemato-oncology medical office

Landshut, Germany

Klinikum Leverkusen GmbH

Leverkusen, Germany

St. Marienkrankenhaus

Ludwigshafen, Germany

Community based hemato-oncology medical office

Lüdenscheid, Germany

Universitätsklinik Mainz

Mainz, Germany

Community based hemato-oncology medical office

Marburg, Germany

Community based hemato-oncology medical office

Mönchengladbach, Germany

Community based hemato-oncology medical office

München, Germany

University Clinic Großhadern

München, Germany

Community based hemato-oncology medical office

Neumarkt, Germany

Community based hemato-oncology medical office

Nuremberg, Germany

Community based hemato-oncology medical office

Nuremberg, Germany

St. Clemens Hospital

Oberhausen, Germany

St. Martinus-Hospital

Olpe, Germany

Community based hemato-oncology medical office

Osnabrück, Germany

St. Josefs-Krankenhaus

Potsdam, Germany

Community based hemato-oncology medical office

Rehling, Germany

Community based hemato-oncology medical office

Rüsselsheim am Main, Germany

Caritas Klinik St. Theresia

Saarbrücken, Germany

Community based hemato-oncology medical office

Schkeuditz, Germany

Kreiskrankenhaus Schotten

Schotten, Germany

Community based hemato-oncology medical office

Schweinfurt, Germany

Community based hemato-oncology medical office

Siegen, Germany

St.-Marien-Krankenhaus

Siegen, Germany

Diakonie - Klinikum Stuttgart

Stuttgart, Germany

Community based hemato-oncology medical office

Trier, Germany

Community based hemato-oncology medical office

Tübingen, Germany

University Clinic Ulm

Ulm, Germany

Städtisches Krankenhaus Villingen

Villingen-Schwenningen, Germany

Community based hemato-oncology medical office

Weilheim, Germany

Sophien- und Hufeland Klinikum

Weimar, Germany

Asklepios Nordseeklinik

Westerland, Germany

Community based hemato-oncology medical office

Wiesbaden, Germany

Dr. Horst-Schmidt-Kliniken

Wiesbaden, Germany

Community based hemato-oncology medical office

Wilhelmshaven, Germany

Community based hemato-oncology medical office

Wolfsburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT02131753

Related Trials

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

NCT069651144 locations

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

NCT0656136010 locations

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

NCT043241121 location

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

NCT043223831 location

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

NCT048153561 location